Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Short-term Investments (2022 - 2025)

Historic Short-term Investments for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to $228.7 million.

  • ARS Pharmaceuticals' Short-term Investments rose 3860.47% to $228.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.7 million, marking a year-over-year increase of 3860.47%. This contributed to the annual value of $263.2 million for FY2024, which is 6723.21% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Short-term Investments of $228.7 million as of Q3 2025, which was up 3860.47% from $188.6 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Short-term Investments registered a high of $263.2 million during Q4 2024, and its lowest value of $19.9 million during Q1 2022.
  • Moreover, its 4-year median value for Short-term Investments was $167.6 million (2024), whereas its average is $151.1 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first skyrocketed by 78975.22% in 2023, then crashed by 904.39% in 2024.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' Short-term Investments stood at $63.9 million in 2022, then soared by 146.45% to $157.4 million in 2023, then surged by 67.23% to $263.2 million in 2024, then decreased by 13.13% to $228.7 million in 2025.
  • Its last three reported values are $228.7 million in Q3 2025, $188.6 million for Q2 2025, and $235.9 million during Q1 2025.